Phase Ib/II Study Of The Combination Of Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Latest Information Update: 10 Dec 2025
At a glance
- Drugs Cemiplimab (Primary) ; Imiquimod (Primary)
- Indications Basal cell cancer; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CEMIQUID
Most Recent Events
- 26 Nov 2025 Status changed from not yet recruiting to recruiting.
- 23 Sep 2025 New trial record